Evidence map›Paper›PMID 39829931›Full record

ArticlebioRxiv : the preprint server for biology2025

The Chimeric Peptide (GEP44) Reduces Body Weight and Both Energy Intake and Energy Expenditure in Diet-Induced Obese Rats.

Matvey Goldberg, James E Blevins, Tami Wolden-Hanson, Clinton T Elfers, Kylie S Chichura, Emily F Ashlaw, Laura J den Hartigh, Christian L Roth, Robert P Doyle

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Matvey GoldbergVA Puget Sound Health Care System, Office of Research and Development Medical Research Service, Department of Veterans Affairs Medical Center, Seattle, WA 98108, USA.
James E BlevinsVA Puget Sound Health Care System, Office of Research and Development Medical Research Service, Department of Veterans Affairs Medical Center, Seattle, WA 98108, USA.ORCID 0000-0002-7587-0380
Tami Wolden-HansonVA Puget Sound Health Care System, Office of Research and Development Medical Research Service, Department of Veterans Affairs Medical Center, Seattle, WA 98108, USA.
Clinton T ElfersSeattle Children's Research Institute, Seattle, WA, United States 98195, USA.
Kylie S ChichuraDepartment of Chemistry, Syracuse University, Syracuse, NY 13244, USA.
Emily F AshlawDepartment of Chemistry, Syracuse University, Syracuse, NY 13244, USA.
Laura J den HartighDivision of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.ORCID 0000-0002-6789-5916
Christian L RothSeattle Children's Research Institute, Seattle, WA, United States 98195, USA.ORCID 0000-0003-3037-4057
Robert P DoyleDepartment of Chemistry, Syracuse University, Syracuse, NY 13244, USA.ORCID 0000-0001-6786-5656

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1986 to 2026
$41.4M
The National Center for Metabolic Phenotyping of Mouse Models of Obesity and Diabetes (MPMOD) at UC DavisU2CDK135074 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Jill Lynn Silverman · 2023 to 2026
$4.0M
Development of Anorexigenic and Glucoregulatory Chimeric PeptidesR01DK135125 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Robert P Doyle, Christian Ludwig Roth · 2023 to 2026
$2.7M
Distinct functions of adipocyte-derived FGF21 in obesityR01DK135756 · NIDDK · UNIVERSITY OF WASHINGTON · PI Laura J. den Hartigh · 2024 to 2026
$1.5M
Role of Brown Adipose Tissue Thermogenesis in Oxytocin-Elicited Weight LossR01DK115976 · NIDDK · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · PI BLEVINS, JAMES ERNEST · 2018 to 2021
$1.4M
BLRD VA I01 BX004102NIDDK NIH HHS P30 DK017047NIDDK NIH HHS R01 DK115976NIDDK NIH HHS R01 DK135125NIDDK NIH HHS R01 DK135756NIDDK NIH HHS U2C DK135074
6 · The paper itself

Abstract

We recently reported that a chimeric peptide (GEP44) targeting the glucagon-like peptide-1 receptor (GLP-1R) and neuropeptide Y1- and Y2- receptors decreased body weight (BW), energy intake and core temperature in diet-induced obese (DIO) male and female mice. In the current study, we tested the hypothesis that the strong reduction of body weight in response to GEP44 is partially related to the stimulation of energy expenditure (EE). To test this, rats were maintained on a HFD for at least 4 months to elicit DIO prior to undergoing a sequential 2-day vehicle period, 2-day GEP44 (50 nmol/kg) period and a minimum 2-day washout period and detailed measures of energy homeostasis. GEP44 (50 nmol/kg) reduced EE (indirect calorimetry), respiratory exchange ratio (RER), core temperature, activity, energy intake and BW in male and female rats. As in our previous study in mice, GEP44 reduced BW in male and female HFD-fed rats by 3.8 ± 0.2% and 2.3 ± 0.4%, respectively. These effects appear to be mediated by increased lipid oxidation and reductions of energy intake as GEP44 reduced RER and cumulative energy intake in male and female HFD-fed rats. The strong reduction of body weight in response to GEP44 is related to a robust reduction of energy intake, but not to stimulation of EE. The paradoxical finding that GEP44 reduced EE might be secondary to a reduction of diet-induced thermogenesis or might indicate an important mechanism to limit the overall efficacy of GEP44 to prevent further weight loss.

Indexed as

GLP-1iBATiWATmulti-agonistObesityPYY

Identifiers

PMID39829931
PMCPMC11741413

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.